TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06413966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partially absorbable mesh
Description: - In this group, after bullectomy or blebectomy, partially absorbable mesh (ULTRAPRO size 15 x 15 cm, Ethicon) will be prepared and inserted into the pleural cavity through one of the working ports and placed at the apical part of the thoracic cage (over the staple line) using fixation device (ProTack™ 5 mm fixation device, Medtronic).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apical pleurectomy
Description: - In apical pleurectomy group, after bullectomy or blebectomy, the parietal surface from the apex to the fifth rib was dissected and abraded using a curved dissector with a diathermy scratch pad. Abrasion was done until a uniform aspect of bloody pleura was obtained.
Study: NCT06612008

Intervention type: DEVICE
Intervention: Mandibular Advancement Device
Description: MADs are custom-fitted oral appliances designed to reposition the mandible (lower jaw) forward during sleep, which helps to keep the airway open by preventing upper airway collapse.

Intervention type: DEVICE
Intervention: Mandibular Advancement Device
Description: MADs are custom-fitted oral appliances designed to reposition the mandible (lower jaw) forward during sleep, which helps to keep the airway open by preventing upper airway collapse.
Study: NCT06548282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: Introduction: Build rapport and complete pre-assessment questionnaires.~First Session:~Introduce therapist, ACT principles, and MI complications. Provide psychoeducation and assign homework.~Second Session:~Review feedback and encourage change. Assign homework.~Third Session:~Discuss acceptance and coping strategies. Assign homework.~Fourth Session:~Discuss cognitive diffusion and unhelpful thoughts. Assign homework.~Fifth Session:~Explore self-concept and mindfulness. Assign homework.~Sixth Session:~Identify and elaborate on values. Assign homework.~Seventh Session:~Discuss values, goals, and barriers. Assign homework.~Eighth Session:~Discuss commitment to action and relapse prevention. Administer post-test and express gratitude.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and commitment therapy
Description: Introduction: Build rapport and complete pre-assessment questionnaires.~First Session:~Introduce therapist, ACT principles, and MI complications. Provide psychoeducation and assign homework.~Second Session:~Review feedback and encourage change. Assign homework.~Third Session:~Discuss acceptance and coping strategies. Assign homework.~Fourth Session:~Discuss cognitive diffusion and unhelpful thoughts. Assign homework.~Fifth Session:~Explore self-concept and mindfulness. Assign homework.~Sixth Session:~Identify and elaborate on values. Assign homework.~Seventh Session:~Discuss values, goals, and barriers. Assign homework.~Eighth Session:~Discuss commitment to action and relapse prevention. Administer post-test and express gratitude.
Study: NCT05619471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIO Imaging
Description: Skin conditions that are candidates for skin biopsies
Study: NCT04798157

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: transcranial doppler
Description: Transcranial Doppler ultrasonography will be done using the ultrasound machine by placing a transducer over the relatively thinner temporal and occipital bones in order to visualize and evaluate the velocities at the circle of Willis.
Study: NCT05623410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATGC-110
Description: ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin®
Description: Xeomin® is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
Study: NCT06109389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: LIDOCAINE INFUSION STARTED 3 MG PER KG FOR 2 SUCCESSIVE WEEKS ,THEN 4 MG PER KG FOR ANOTHER 2 WEEKS .ONCE WEEKLY,other group saline infusion once weekly for 4 successive weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: LIDOCAINE INFUSION STARTED 3 MG PER KG FOR 2 SUCCESSIVE WEEKS ,THEN 4 MG PER KG FOR ANOTHER 2 WEEKS .ONCE WEEKLY,other group saline infusion once weekly for 4 successive weeks
Study: NCT05524064

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FLASH Radiotherapy
Description: A dose of 8 Gy delivered in a single fraction will be prescribed to the PTV, delivered with FLASH Radiotherapy (\>40 Gy/s).
Study: NCT06438211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superficial or deep serratus anterior plane block for mastectomy
Description: group I: superficial SAP Block for postoperative analgesia for mastectomy group II: deep SAP Block for postoperative analgesia for mastectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superficial or deep serratus anterior plane block for mastectomy
Description: group I: superficial SAP Block for postoperative analgesia for mastectomy group II: deep SAP Block for postoperative analgesia for mastectomy
Study: NCT05583097

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Non-selective cytology
Description: All noduleas are evaluated according to EU-TIRADS. Cytology performed on all nodules larger than 1 cm regardless of ultrasonographic features. Nodules 1 cm or smaller evaluated as EU-TIRADS 5 undergo cytologic examination if possible.
Study: NCT06524388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adaptive cognitive training
Description: The intervention was computerized, multi-domain, adaptive cognitive training. Training areas include processing speed, attention, perception, long-term memory, working memory, computation, executive control, reasoning, and problem-solving. Embedded in the Adaptive Cognitive training application is an adaptive algorithm that will help provide each participant with a cognitive training task at the right level of difficulty based on their profile and real-time performance.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo cognitive training
Description: Participants received cognitive training tasks of fixed difficulty.
Study: NCT04331288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT150
Description: Intervention 1 includes PT150 with alcohol consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage
Description: The alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in juice or another flavored beverage. Participants will be allowed 30 minutes to consume the beverages.
Study: NCT05932758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted excisional biopsy
Description: at least 4g of tissue sampled (excisional biopsy)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Not excisional biopsy
Description: biopsy with less than 4 g of tissue sampled
Study: NCT05439746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microlyte® Matrix
Description: Microlyte® Matrix is indicated for the management of wounds and can be used over-the-counter for minor wounds such as abrasions and lacerations, minor cuts, and minor scalds and burns. Under the direction of a healthcare professional, Microlyte® Matrix may be used for more serious wounds such as partial and full thickness pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds. Microlyte® Matrix may be used over debrided and grafted partial thickness wounds.
Study: NCT04828031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patient with inflammatory bowel disease who have low vitamin D (25(OH)D less than or equal to 25 ng/mL) will take Vitamin D 50,000 IU by mouth every week for 12 weeks. Patients will fill out questionnaires to document disease activity score (HBI or Mayo score and sIBDQ) and have blood and stool samples collected before (Week 0), during (Week 8) and after (Week 12) vitamin D intervention.
Study: NCT04155463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic Diet
Description: Participants receive one week of organic food. Organic food is certified through the USDA's National Organic Program as produced without the use of synthetic pesticides, including glyphosate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic Diet
Description: Participants receive one week of organic food. Organic food is certified through the USDA's National Organic Program as produced without the use of synthetic pesticides, including glyphosate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Diet
Description: Participants receive one week of conventionally grown (non-organic) food.
Study: NCT06458413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Capsule Plus Capecitabine
Description: Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14.~Every 21 days is a cycle .
Study: NCT04993482

Intervention type: OTHER
Intervention: No intervention
Description: This project contains a longitudinal observational study design. The investigator will collect data out of a group with type 2 diabetes mellitus patients and out of group with control adults on three time points (baseline, follow-up after one year, and follow-up after two years). Therefore, the investigator will only collect observational data and the participants will not be exposed to a certain intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This project contains a longitudinal observational study design. The investigator will collect data out of a group with type 2 diabetes mellitus patients and out of group with control adults on three time points (baseline, follow-up after one year, and follow-up after two years). Therefore, the investigator will only collect observational data and the participants will not be exposed to a certain intervention.
Study: NCT04155463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Diet
Description: Participants receive one week of conventionally grown (non-organic) food.
Study: NCT06474156

Intervention type: BEHAVIORAL
Intervention: Multidimensional Family Therapy
Description: Multidimensional family therapy is a manualized,evidence-based, intensive intervention program with assessment and treatment modules focusing on four areas: (a) the individual adolescents' issues regarding substance use disorder, delinquency, and comorbid psychopathology, (b) the parents' child-rearing skills and personal functioning, (c) communication and relationship between adolescent and parent(s), and (d) interactions between family members and key social systems (Liddle, 2002).

Intervention type: BEHAVIORAL
Intervention: Multidimensional Family Therapy
Description: Multidimensional family therapy is a manualized,evidence-based, intensive intervention program with assessment and treatment modules focusing on four areas: (a) the individual adolescents' issues regarding substance use disorder, delinquency, and comorbid psychopathology, (b) the parents' child-rearing skills and personal functioning, (c) communication and relationship between adolescent and parent(s), and (d) interactions between family members and key social systems (Liddle, 2002).
Study: NCT05442060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg OBI-833/100 μg OBI-821
Description: Each subject in the OBI-833/OBI-821 + erlotinib combination arm will be treated with OBI-833/OBI-821 weekly for 4 doses (Weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (Weeks 6, 8), then every 4 weeks for 4 doses (Weeks 12, 16, 20, 24), and then every 8 weeks until documented disease progression, intolerable adverse events (AEs)/toxicity, consent withdrawal, death, loss to follow-up, or up to 80 weeks from randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib (150 mg daily)
Description: All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily)
Description: All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).
Study: NCT05070013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: All subjects will undergo three 1-week conditions of stimulation during nighttime sleep over the course of three consecutive weeks of in-home sleep: adaptive stimulation, open-loop stimulation and no stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: All subjects will undergo three 1-week conditions of stimulation during nighttime sleep over the course of three consecutive weeks of in-home sleep: adaptive stimulation, open-loop stimulation and no stimulation.
Study: NCT06431464

Intervention type: OTHER
Intervention: picosecond laser treatment + measurement with a multiphoton tomography system
Description: Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
Study: NCT04893577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDTA
Description: Patients will treat their cold sore with EDTA eye drops based upon their randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abreva
Description: Patients will treat their cold sore with Abreva based upon their randomization
Study: NCT06431464

Intervention type: OTHER
Intervention: nanosecond laser treatment + measurement with a multiphoton tomography system
Description: Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
Study: NCT04676061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone acetate (NTA)
Description: norethindrone acetate, 5 mg tablet, orally, once daily for 7 consecutive days, every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks
Study: NCT05759039

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial patellofemoral ligament reconstruction
Description: Medial patellofemoral ligament reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial patellofemoral ligament reconstruction
Description: Medial patellofemoral ligament reconstruction
Study: NCT04617275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: PF-68882961 will be provided as tablets twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: PF-68882961 will be provided as tablets twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: PF-68882961 will be provided as tablets twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: PF-68882961 will be provided as tablets twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: PF-68882961 will be provided as tablets twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: PF-68882961 will be provided as tablets twice a day (BID)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator will be provided as tablets twice daily for 12 weeks
Study: NCT06350760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active control condition
Description: The active control condition will be based on PROCARE protocol, which was put into practice in PROCARE-I, in 2021.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE-I+ 8-session
Description: The active control condition will be based on PROCARE protocol, which was put into practice in PROCARE-I, in 2021. In addition, PROCARE-I+ adds additional modules, which allow adolescents to be provided with tools to address the risk factors they present.
Study: NCT05119179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Glucagon-like Peptide 1 Receptor Agonist
Study: NCT05412004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05026944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percussive massage and static stretching exercises
Description: All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be treated with 5 minutes of percussive massage and 5 minutes of static stretching exercises. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.

Intervention type: OTHER
Group type: OTHER
Intervention: static stretching exercises
Description: All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be managed with 5 minutes of static stretching exercises only. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
Study: NCT06423664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play and Learn Strategies (PALS) Program
Description: Monthly modules and personalized coaching sessions designed to strengthen maternal responsiveness and sensitivity which, in turn, improves infant social-emotional behavior and development outcomes.
Study: NCT06423690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAS1 System
Description: tumor ablation system in IRE method
Study: NCT06663592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: hot pack, stretching of the neck muscles, cervical isometrics exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tensioner Neuro Dynamic Mobilization
Description: Median nerve tensioner neural mobilization with addition to conventional treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slider Neuro Dynamic Mobilization
Description: Median nerve neural sliding mobilization with addition to conventional treatment
Study: NCT06336356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Baxdrostat will be administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally once daily.
Study: NCT05883865

Intervention type: DRUG
Intervention: Fenofibrate
Description: Fenofibrate is orally administrated daily with food for at least 1 week during pregnancy
Study: NCT05653232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylaxis (P2W)
Description: For participants enrolled in P2W arm, the initial dose of SOF/VEL will be administered to the recipient when called to the operating room for transplant (typically 1-3 hours prior to the start of surgery). Post-transplant, SOF/VEL will be continued daily for 13 days post-KT (a total of 14 doses administered).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transmit and Treat (T&T)
Description: For participants enrolled in T\&T arm, SOF/VEL will begin between post-KT day 0 and post-KT day 14. Participants will be clinically-prescribed DAAs once viremia is detected, and participant's insurance will be petitioned to obtain treatment as soon as possible. If insurance-provided DAAs are approved before post-KT day 14, participant will begin 12 weeks of study-provided SOF/VEL on date of insurance-provided DAAs approval. If insurance-provided DAAs are not approved by post-KT day 14, study-provided SOF/VEL will begin on post-KT day 14 and continue for 12 weeks.
Study: NCT04535427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Study: NCT06037317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-3505
Description: LTK tyrosine kinase inhibitor